Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022
Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine. No safety signals were identified using a multipronged approach of...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Centers for Disease Control and Prevention
2024-04-01
|
| Series: | Emerging Infectious Diseases |
| Subjects: | |
| Online Access: | https://wwwnc.cdc.gov/eid/article/30/4/23-1361_article |
| _version_ | 1797248678124060672 |
|---|---|
| author | Farrell A. Tobolowsky Fred Nsubuga Zunera Gilani Annet Kisakye Helen Ndagije Daniel Kyabayinze Jane F. Gidudu |
| author_facet | Farrell A. Tobolowsky Fred Nsubuga Zunera Gilani Annet Kisakye Helen Ndagije Daniel Kyabayinze Jane F. Gidudu |
| author_sort | Farrell A. Tobolowsky |
| collection | DOAJ |
| description |
Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine. No safety signals were identified using a multipronged approach of passive and active surveillance.
|
| first_indexed | 2024-04-24T20:18:24Z |
| format | Article |
| id | doaj.art-5d4297f3108c4dc5a08a19f5375cb735 |
| institution | Directory Open Access Journal |
| issn | 1080-6040 1080-6059 |
| language | English |
| last_indexed | 2024-04-24T20:18:24Z |
| publishDate | 2024-04-01 |
| publisher | Centers for Disease Control and Prevention |
| record_format | Article |
| series | Emerging Infectious Diseases |
| spelling | doaj.art-5d4297f3108c4dc5a08a19f5375cb7352024-03-22T12:19:27ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592024-04-0130477577810.3201/eid3004.231361Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022Farrell A. TobolowskyFred NsubugaZunera GilaniAnnet KisakyeHelen NdagijeDaniel KyabayinzeJane F. Gidudu Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine. No safety signals were identified using a multipronged approach of passive and active surveillance. https://wwwnc.cdc.gov/eid/article/30/4/23-1361_articlevirusespoliovirusvaccinesvaccine safetyUganda |
| spellingShingle | Farrell A. Tobolowsky Fred Nsubuga Zunera Gilani Annet Kisakye Helen Ndagije Daniel Kyabayinze Jane F. Gidudu Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022 Emerging Infectious Diseases viruses poliovirus vaccines vaccine safety Uganda |
| title | Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022 |
| title_full | Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022 |
| title_fullStr | Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022 |
| title_full_unstemmed | Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022 |
| title_short | Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022 |
| title_sort | novel oral poliovirus vaccine 2 safety evaluation during nationwide supplemental immunization activity uganda 2022 |
| topic | viruses poliovirus vaccines vaccine safety Uganda |
| url | https://wwwnc.cdc.gov/eid/article/30/4/23-1361_article |
| work_keys_str_mv | AT farrellatobolowsky noveloralpoliovirusvaccine2safetyevaluationduringnationwidesupplementalimmunizationactivityuganda2022 AT frednsubuga noveloralpoliovirusvaccine2safetyevaluationduringnationwidesupplementalimmunizationactivityuganda2022 AT zuneragilani noveloralpoliovirusvaccine2safetyevaluationduringnationwidesupplementalimmunizationactivityuganda2022 AT annetkisakye noveloralpoliovirusvaccine2safetyevaluationduringnationwidesupplementalimmunizationactivityuganda2022 AT helenndagije noveloralpoliovirusvaccine2safetyevaluationduringnationwidesupplementalimmunizationactivityuganda2022 AT danielkyabayinze noveloralpoliovirusvaccine2safetyevaluationduringnationwidesupplementalimmunizationactivityuganda2022 AT janefgidudu noveloralpoliovirusvaccine2safetyevaluationduringnationwidesupplementalimmunizationactivityuganda2022 |